Retatrutide is a new pharmaceutical in the fight against obesity. This novel drug, categorized as a dual GLP-1 and GIP receptor agonist, demonstrates promising results in investigations. By boosting these receptors, Retatrutide suppresses appetite, {promotesenergy expenditure, and ultimately contrib